The Zollinger-Ellison Syndrome: A Comprehensive Review of Historical, Scientific, and Clinical Considerations

Current Problems in Surgery

Volumn 46, Issue 1, 2009, Pages 13-106

  Ellison, E Christopher ^a   Johnson, Jerome A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMOGRANIN A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FLUORODEOXYGLUCOSE F 18; GASTRIN; LANSOPRAZOLE; METHIONINE; MYC PROTEIN; OMEPRAZOLE; PANTOPRAZOLE; PENTETREOTIDE IN 111; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P53; PROTEIN RET; PROTON PUMP INHIBITOR; RABEPRAZOLE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SECRETIN; SMAD PROTEIN; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR ALPHA; VON HIPPEL LINDAU PROTEIN;

ABDOMINAL PAIN; ABDOMINAL SCINTISCANNING; ANAMNESIS; ARTICLE; ARTIFICIAL EMBOLISM; BALLOON DILATATION; CARDIOPULMONARY ARREST; CHEMOEMBOLIZATION; CHILD CARE; CHROMOSOME 1; CHROMOSOME 22Q; CHROMOSOME 3; CHROMOSOME 5; CHROMOSOME ABERRATION; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIAPHORESIS; DIARRHEA; DRUG MEGADOSE; DYSPNEA; ELDERLY CARE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGOGASTROSTOMY; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; FAMILY HISTORY; GASTRINOMA; GASTROJEJUNOSTOMY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG LESION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATICODUODENECTOMY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PROVOCATION TEST; RADIOFREQUENCY ABLATION; RECOMMENDED DRUG DOSE; REFLUX ESOPHAGITIS; SPIROMETRY; STOMACH OBSTRUCTION; SURGICAL TECHNIQUE; SURVIVAL RATE; THORACOTOMY; TOTAL PARENTERAL NUTRITION; TUBE FEEDING; TUMOR VOLUME; VAGOTOMY; ZOLLINGER ELLISON SYNDROME;

AGED; CALCIUM; CHILD; GASTRINOMA; GASTRINS; HISTORY, 20TH CENTURY; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; SECRETIN; ZOLLINGER-ELLISON SYNDROME;

EID: 57049098034     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2008.09.001     Document Type: Article

References (216)

1. Zollinger R.M., and Ellison E.H. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142 (1955) 709-728
2. Zollinger R.M., and Coleman D.W. The Influences of Pancreatic Tumors on the Stomach (1974), Charles C. Thomas, Springfield, IL
3. Ellison E.H. The ulcerogenic tumor of the pancreas. Surgery 40 (1956) 147-170
4. Gregory R.A., Tracy H.J., French J.M., et al. Extraction of a gastrin-like substance from a pancreatic tumor in a case of Zollinger-Ellison syndrome. Lancet 1 (1960) 1045-1048
5. Underdahl L.O., Woolner L.B., and Black B.M. Multiple endocrine adenomas: report of 8 cases in which the parathyroids, pituitary, and pancreatic islets were involved. J Clin Endocrin Metab 13 (1953) 20-24
6. Wermer P. Genetic aspects of adenomatosis of the endocrine glands. Am J Med 16 (1954) 363-371
7. Oberhelman H.A., and Nelson T.S. Surgical considerations in the management of ulcerogenic tumors of the pancreas and duodenum. Am J Surg 108 (1964) 132-141
8. Berson S.A., and Yalow R.L. Immunoassay of endogenous insulin in man. J Clin Invest 39 (1960) 1157-1175
9. McGuigan J.D., and Trudeau W.L. Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. N Engl J Med 278 (1968) 1308-1313
10. Isenberg J.I., Walsh J.H., Passaro E., et al. Unusual effect of secretin on serum gastrin, serum calcium, and gastric acid secretion in a patient with suspected Zollinger-Ellison syndrome. Gastroenterology 62 (1972) 626-631
11. Stabile B.E., Morrow D.J., and Passaro Jr. E. The gastrinoma triangle: operative implications. Am J Surg 147 (1984) 25-31
12. Thompson N.W., Vinik A.I., and Eckhauser F.E. Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome. Ann Surg 209 (1989) 396-404
13. Norton J.A., Alexander H.R., Fraker D.L., Venzon D.J., Gibril F., and Jensen R.T. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?. Ann Surg 239 (2004) 617-625
14. Beaumont W. Experiments and Observations on the Gastric Juice and the Physiology of Digestion (1833), F. P. Allen, Flattsburg
15. Khizhin P. Activite secretoine de l'estomac du chien. Arch Sci Biol (St. Petersburg) 3 (1894) 461-469
16. Lobasov I.O. Sur l'excitabilite secretoire specifique de la muqueuse du canal digestif. Arch Sci Biol (St. Petersburg) 5 (1897) 425-437
17. Lecorte P. Functions gastrointestinales etude physiologique. La Cellule 17 (1900) 283-296
18. Bayliss W.M., and Starling E.H. The mechanism of pancreatic secretion. J Physiol 28 (1902) 325-353
19. Edkins J.S. On the chemical mechanism of gastric secretion. Proc R Soc 76 (1905) 376-391
20. Gross W., and Pavlov I. Contribution to the conditions of gastric secretion according to experiments on the dog. Arch f Vendauungshnank 12 (1906) 507-528
21. Maydell B.E. The question of the gastric secretion. Pfluger's Arch 150 (1913) 390-404
22. Tomaszewski Z. Uber die chemischen Erregen der Mageridrusen. Pfluger's Arch 170 (1918) 260-312
23. Lim R.K. The question of a gastrin hormone. Q J Exp Physiol 13 (1922) 79-103
24. Orbeli L. Secretory potential of gastric mucosal extracts. Arch Sci Biol (St. Petersburg) 12 (1907) 71-93
25. Emsman M. Uber hamatogene Erregung Von Magenseknetion durch salzsanne Extrakte der Grossen drusigen Organe des Korpens Und des Darminhaltes. Int Beitr z Pathol u Therap d Drahaungstorungen 3 (1912) 117-135
26. Keeton R., and Koch F. The distribution of gastrin in the body. Am J Physiol 37 (1915) 481-504
27. Popielski L. The physiological and chemical properties of Witte Peptone. Pfluger's Arch 128 (1909) 222-225
28. Zeliony G.P. Non-normal gastric secretion. Arch Sci Biol (St. Petersburg) 17 (1913) 425-437
29. Dale H.H., and Laidlaw P.P. Physiological action of β-iminazolyethylamine. J Physiol 41 (1910) 318-344
30. Koch F.C., Luckhandt A.B., and Keeton R.W. Gastrin studies. Am J Physiol 52 (1920) 508-520
31. Ivy A., and Farrell J. Proof of a humoral mechanism of gastric secretion. Am J Physiol 74 (1925) 639-649
32. Lim R.K., and Loo L. Gastric secretion. Chin J Physiol 1 (1927) 51-82
33. Necheles H., and Lim R. Demonstration of a gastric secretory exitant in circulating blood by vivi-dialysis. Proc Soc Exp Biol Med (NY) 24 (1927) 197-213
34. Best C.H., and McHenry E. Disappearance of histamine from autolysis lung tissue. J Physiol 67 (1929) 256-263
35. Sacks J., Ivy A., Burgess J., and Vandolah J. Histamine as the hormone for gastric secretion. Am J Physiol 101 (1932) 331-338
36. Gavin G., McHenry E., and Wilson M. Histamine in canine gastric tissues. J Physiol 79 (1933) 234-238
37. Komarov S.A. Gastrin. Soc Exp Biol Med 38 (1938) 514-516
38. Ivy A. Mechanism of gastric secretion. Surgery 10 (1941) 861-878
39. Grossman M. Gastrointestinal hormones. Physiol Rev 30 (1950) 33-90
40. Uvnas B. The gastric secretory exitant from the pyloric mucosa. Acta Physiol Scand 6 (1943) 97-107
41. Jorpes J., Jailing O., and Mutt V. A method for the preparation of gastrin. Biochem J 52 (1952) 327-328
42. Gregory R., and Tracy H. The preparation and properties of gastrin. J Physiol 149 (1959) 70-71
43. Gregory R., and Tracy H. Preparation and properties of gastrin. J Physiol 156 (1961) 523-543
44. Gregory R., Hardy P., Jones D., et al. Structure of gastrin. Nature 204 (1964) 931-933
45. Anderson J., Barton M., Gregory R., et al. Synthesis of gastrin. Nature 204 (1964) 933-935
46. Grossman M., Tracy H., and Gregory R. Isolation of a gastrin-like substance from the primary and secondary tumor. Gastroenterology 41 (1961) 87-91
47. Yalow R., and Berson S. Size and charge distinctions between endogenous human plasma gastrin in peripheral blood and heptadecapeptide gastrins. Gastroenterology 58 (1970) 609-615
48. Gregory R., and Tracy H. Isolation of two "big gastrins" from Zollinger-Ellison tumor tissue. Lancet 2 (1972) 797-799
49. Yalow R., and Berson S. And now "big-big" gastrin. Biochem Biophys Res Commun 48 (1972) 391-395
50. Rehfeld J.F. Three components of gastrin in human serum: gel filtration studies on the molecular size of immunoreactive serum gastrin. Biochim Biophys Acta 285 (1972) 364-372
51. Gregory R., and Tracy H. Isolation of two mini-gastrins from Zollinger-Ellison tumor tissue. Gut 15 (1974) 683-685
52. Rehfeld J. Gastrin heterogeneity in serum and tissue. In: Thompson J.C. (Ed). G.I. Hormones (1975), University of Texas Press, Austin 43-57
53. Ito R., Sato K., Helmer T., et al. Structural analysis of the gene encoding human gastrin: the large intron contains an Alu sequence. Proc Natl Acad of Sci USA 81 (1984) 4662-4666
54. Yoo O.J., Powell C.T., and Agarwal K.L. Molecular cloning and nucleotide sequence of full length gastrin cDNA coding for porcine gastrin. Proc Natl Acad Sci USA 79 (1982) 1049-1057
55. Wiborg O., Berglund L., Boel E., et al. Structure of the human gastrin gene. Proc Natl Acad Sci USA 81 (1984) 1067-1074
56. Varro A., and Ardill J.E. Gastrin: an analytical review. Ann Clin Biochem 40 (2003) 472-480
57. Rehfeld J.F., and Johnsen A.H. Identification of gastrin component 1 as gastrin-71. The largest possible bioactive progastrin product. Eur J Biochem 223 (1994) 765-773
58. Jackson B.M., Reeder D.D., and Thompson J.C. Dynamic characteristics of gastrin release. Am J Surg 123 (1972) 137-146
59. Ganguli P.C. The effect of protein, carbohydrate, or fat on plasma gastrin concentration in human subjects. Gut 11 (1970) 1061
60. Feldman M., Richardson C.T., Taylor I.L., et al. Effect of atropine on vagal release of gastrin and pancreatic polypeptide. J Clin Invest 63 (1979) 294-298
61. McGuigan J.E., and Trudeau W.L. Serum gastrin levels before and after vagotomy or pyloroplasty and antrectomy. N Engl J Med 286 (1972) 184-188
62. Hollinshead J.W., Debas H.T., Yamada T., et al. Hypergastrinemia develops within 24 hours of truncal vagotomy in dogs. Gastroenterology 88 1 Pt 1 (1985) 35-40
63. Raptis S., Dollinger H.C., von Berger L., et al. Effects of somatostatin on gastric secretion and gastrin release in man. Digestion 13 (1975) 15-26
64. Jensen R.T. Overview of chronic diarrhea caused by functional neuroendocrine neoplasms [review]. Semin Gastrointest Dis 10 (1999) 156-172
65. Roy P.K., Venzon D.J., Shojamanesh H., et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine 79 (2000) 379-411
66. Zollinger R.M., and Grant G.N. Ulcerogenic tumor of the pancreas. JAMA 190 (1964) 93-96
67. Corleto V.D., Annibale B., and Gibril F. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?. Gastroenterology 116 (1999) A1117
68. Ellison E.C., and Sparks J.S. Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors?. Am J Surg 186 (2003) 245-248
69. Corleto V.D., Delle Fave G., and Jensen R.T. Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances. Dig Liver Dis 34 (2002) 668-680
70. Gartner W., Mineva I., Daneva T., et al. A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients. Hum Genet 117 (2005) 143-153
71. Evers B.M., Radt P.L., and Sandoval K. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann Surg 219 (1994) 596-604
72. Goebel S.U., Iwamoto M., Raffeld M., et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 62 (2002) 3702-3710
73. Speel E.J., Richter L., Moch H., et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 155 (1999) 1787-1794
74. Guru S.C., Goldsmith P.K., Burns A.L., et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 95 (1998) 1630-1634
75. Pritchard D.M. Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1. Gut 56 (2007) 606-607
76. Marx S.J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5 (2005) 367-375
77. Crabtree J.S., Scacheri P.C., Ward J.M., et al. A mouse model of multiple endocrine neoplasia type 1 develops multiple endocrine tumors. Pro Natl Acad Sci USA 98 (2001) 118-123
78. Bertolino P., Tong W.M., Galendo D., et al. Heterozygous MEN1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 17 (2003) 1880-1892
79. Loffler K.A., Biondi C.A., Gartside M., et al. Broad tumor spectrum in a mouse of multiple endocrine neoplasia type 1. Int J Cancer 120 (2007) 259-267
80. Marx S.J., Agarwal S.K., Heppner C., et al. The gene for multiple endocrine neoplasia type 1: recent findings. Bone 25 (1999) 119-122
81. Zhuang Z., Vortmeyer A.O., Pack S., et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57 (1997) 4682-4686
82. Debelenko L.V., Zhuang Z., Emmert-Buck M.R., et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 57 (1997) 2238-2243
83. Sawicki M.P., Wan Y.J., Johnson C.L., et al. Loss of heterozygosity on chromosome 11 in sporadic gastrinomas. Hum Genet 89 (1992) 445-449
84. Eubanks P.J., Sawicki M.P., Samara G.J., et al. Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumors. Am J Surg 167 (1994) 180-185
85. Goebel S.U., Heppner C., Burns A.L., et al. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab 85 (2000) 116-123
86. Cavallari I., D'Agostino D.M., Ferro T., et al. In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. J Clin Endocrinol Metab 88 (2003) 3893-3901
87. Anlauf M., Schlenger R., Perren A., et al. Microadenomatosis of the endocrine pancreas in patients with and without multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 30 (2006) 560-574
88. Vortmeyer A.O., Huange S., Lubensky I., et al. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 89 (2004) 1934-1938
89. Anlauf M., Perren A., Meyer C.L., et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology 128 (2005) 1187-1198
90. Chung D.C., Smith A.P., Louis D.N., et al. Analysis of the retinoblastoma tumor suppressor gene in pancreatic endocrine tumors. Clin Endocrinol (Oxf) 47 (1997) 523-528
91. Bartsch D., Hahn S.A., Danichevski K.D., et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 18 (1999) 2367-2371
92. Serrano J., Goebel S.U., Peghini P.L., et al. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 85 (2000) 4146-4156
93. Muscarella P., Melvin W.S., Fisher W.E., et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 58 (1998) 237-240
94. Furukawa M., Raffeld M., Mateo C., et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 11 (2005) 3233-3242
95. Terris B, Scoazeck JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 1198;32:133-8.
96. Yu F., Jensen R.T., Lubensky I.A., et al. Survey of genetic alterations in gastrinomas. Cancer Res 60 (2000) 5536-5542
97. Chen Y.J., Vortmeyer A., Zhuang Z., et al. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res 63 (2003) 817-823
98. Wild A., Langer P., Celik I., et al. Chromosome 22q in pancreatic endocrine tumors: identification of a homozygous deletion and potential prognostic associations of allelic deletions. Eur J Endocrinol 147 (2002) 507-513
99. Chen Y.J., Vortmeyer A., Zhuang Z., et al. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res 63 (2003) 817-823
100. Long S.H., Berna M.J., Thill M., et al. Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab 92 (2007) 4394-4402
101. Papotti M., Bongiovanni, Volante M., et al. Expresion of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Arch 440 (2002) 461-475
102. Berna M.J., Hoffmann K.M., Serrano J., et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine 85 (2006) 295-330
103. Hansky J., Soveny C., and Korman M.G. Effect of secretin on serum gastrin as measured by radioimmunoassay. Gastroenterology 61 (1971) 62-68
104. Ellison E.C., Gower W.R., Elkhammas E., et al. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue. Am J Med 81 (1986) 56-64
105. Berna M.J., Hoffmann K.M., Long S.H., et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine 85 (2006) 331-364
106. Shibata C., Funayama Y., Fukushima K., et al. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg 12 (2008) 344-349
107. Howard T.J., Sawicki M., Lewin K.J., et al. Pancreatic polypeptide immunoreactivity in sporadic gastrinoma: relationship to intraabdominal location. Pancreas 11 (1995) 350-356
108. Mutch M.G., Frisella M.M., DeBenedetti M.K., et al. Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. Surgery 122 (1997) 1012-1019
109. Syversen U., Mignon M., Bonfils S., et al. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 32 (1993) 161-165
110. Hirschowitz B.I., Worthington J., Mohnen J., et al. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Aliment Pharmacol Ther 26 (2007) 869-878
111. Abou-Saif A., Gibril F., Ojeaburu J.V., et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 98 (2003) 249-261
112. Goebel S.U., Serrano J., Yu F., et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85 (1999) 1470-1483
113. Gibril F., Schumann M., Pace A., and Jensen R.T. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature [review]. Medicine 83 (2004) 43-83 Erratum in: Medicine 2004;83:175
114. Melvin W.S., Johnson J.A., Sparks J., et al. Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery 114 (1993) 1183-1188
115. Karges W., Schaaf L., Dralle H., et al. Concepts for screening and diagnostic follow-up in multiple endocrine neoplasia type 1 (MEN1). Exp Clin Endocrinol Diabetes 108 (2000) 334-340
116. Cardinal J., Bergman N., Hayward N., et al. A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications. J Med Genet 42 (2005) 69-74
117. Noone T.C., Hosey J., Firat Z., et al. Imaging and localization of islet-cell tumors of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 19 (2005) 195-211
118. Imamura M., Minematsu S., Tobe T., Adachi H., and Takahashi K. Selective arterial secretin injection test for localization of gastrinoma. Nippon Geka Gakkai Zasshi 87 (1986) 671-679
119. Imamura M., Takahashi K., Adachi H., et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg 205 (1987) 230-239
120. Doppman J.L., Miller D.L., Chang R., et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology 174 (1990) 25-29
121. Turner J.J., Wren A.M., Jackson J.E., et al. Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf) 57 (2002) 821-825
122. Gibril F., Reynolds J.C., Doppman J.L., et al. Somatostatin receptor scintigraphy: its sensitivity, compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125 (1996) 26-34
123. Alexander H.R., Fraker D.L., Norton J.A., et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 228 (1998) 228-238
124. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 (1999) 635-644
125. Norton J.A., and Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240 (2004) 757-773
126. Norton J.A., McLean A.M., and Fairclogh P.D. Endoscopic ultrasound in the localization of pancreatic islet cell tumors. Best Pract Res Clin Endocrinol Metab 19 (2004) 177-193
127. Anderson M.A., Carpenter S., Thompson N.W., et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 95 (2000) 2271-2277
128. Hayasaka K., Nihashi T., Matsuura T., et al. Usefulness of F-18 FDG-PET in detection of multiple endocrine tumors with duodenal carcinoid. Comput Med Imaging Graph 31 (2007) 191-194
129. Nakamoto Y., Higashi T., Sakahara H., et al. Evaluation of pancreatic islet cell tumors by fluorine-18 fluordeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med 25 (2000) 115-119
130. Jensen R.T. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 98 (2006) 4-19
131. Peghini P.L., Annibale B., Azzoni C., et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 123 (2002) 68-85
132. Metz D.C., Benya R.V., Fishbein V.A., et al. Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection. Aliment Pharmacol Ther 7 (1993) 247-257
133. Termanini B., Gibril F., Sutliff V.E., et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 104 (1998) 422-430
134. Stewart C.A., Termanini B., Sutliff V.E., Corleto V.D., Weber H.C., Gibril F., and Jensen R.T. Management of the Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol 76 (1997) 224-233
135. Mayer A., Sheiner E., and Holcberg G. Zollinger-Ellison syndrome, treated with lansoprazole, during pregnancy. Arch Gynecol Obstet 276 (2007) 171-173
136. Wilson S.D. Zollinger-Ellison syndrome in children: a 25-year follow-up. Surgery 110 (1991) 696-702
137. Tomassetti P., Salomone T., Migliori M., Campana D., and Corinaldesi R. Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients. Drugs Aging 20 (2003) 1019-1034
138. Ellison E.C., Sparks J., Verducci J.S., et al. 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg 202 (2006) 897-905
139. Thompson N.W., Pasieka J., and Fukuuchi A. Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg 17 (1993) 455-462
140. Zogakis T.G., Gibril F., Libutti S.K., Norton J.A., White D.E., Jensen R.T., and Alexander H.R. Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg 238 (2003) 42-48
141. Norton J.A. Surgery and prognosis of duodenal gastrinoma as a duodenal neuroendocrine tumor. Best Pract Res Clin Gastroenterol 19 (2005) 699-704
142. Herrmann M.E., Ciesla M.C., Chejfec G., DeJong S.A., and Yong S.L. Primary nodal gastrinomas. Arch Pathol Lab Med 124 (2000) 832-835
143. Perrier N.D., Batts K.P., Thompson G.B., et al. An immunohistochemical survey for neuroendocrine cells in regional pancreatic lymph nodes: a plausible explanation for primary nodal gastrinomas. Surgery 118 (1995) 957-965
144. Arnold W.S., Fraker D.L., Alexander H.R., et al. Apparent lymph node primary gastrinoma. Surgery 116 (1994) 1123-1130
145. Müssig K., Wehrmann M., Horger M., Bares R., Häring H.U., Gallwitz B., and Petersenn S. Lymph node gastrinoma in multiple endocrine neoplasia type 1-a diagnostic challenge. Exp Clin Endocrinol Diabetes (2008) Apr 1 [Epub ahead of print]
146. Anlauf M., Enosawa T., Henopp T., Schmitt A., Gimm O., Brauckhoff M., et al. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol 32 (2008) 1101-1105
147. Ellison E.C. Forty-year appraisal of gastrinoma: back to the future. Ann Surg 222 (1995) 511-524
148. Noda S., Norton J.A., Jensen R.T., and Gay Jr. W.A. Surgical resection of intracardiac gastrinoma. Ann Thorac Surg 67 (1999) 532-533
149. Liu T.H., Zhong S.X., Chen Y.F., Lin Y., Chen J., Li D.C., et al. Gastric gastrinoma. Chin Med J (Engl) 102 (1989) 774-782
150. Primrose J.N., Maloney M., Wells M., Bulgim O., and Johnston D. Gastrin-producing ovarian mucinous cystadenomas: a cause of the Zollinger-Ellison syndrome. Surgery 104 (1988) 830-833
151. Hirasawa K., Yamada M., Kitagawa M., Takehira Y., Tamakoshi K., Nakamura T., et al. Ovarian mucinous cystadenocarcinoma as a cause of Zollinger-Ellison syndrome: report of a case and review of the literature. Am J Gastroenterol 95 (2000) 1348-1351
152. Abboud P., Bart H., Mansour G., Pinteaux A., and Birembaut P. Ovarian gastrinoma in multiple endocrine neoplasia type I: a case report. Am J Obstet Gynecol 184 (2001) 237-238
153. Smith A.L., and Auldist A.W. Successful surgical resection of an hepatic gastrinoma in a child. J Pediatr Gastroenterol Nutr 3 (1984) 801-804
154. Kanakia R.R., Sawant P.D., Nanivadekar S.A., Vishwanath N., Rajagopalan K., and Shroff C.P. Primary gastrinoma of the liver. Indian Pediatr 31 (1994) 1137-1140
155. Díaz R., Aparicio J., Pous S., Dolz J.F., and Calderero V. Primary hepatic gastrinoma. Dig Dis Sci 48 (2003) 1665-1667
156. Joshi V.V., Nord K.S., and Hanna M. Renal gastrinoma. Fetal Pediatr Pathol 6 (1986) 475-476
157. Martignoni M.E., Friess H., Lübke D., et al. Study of a primary gastrinoma in the common hepatic duct-a case report. Digestion 60 (1999) 187-190
158. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery increases survival in patients with gastrinoma. Ann Surg 244 (2006) 410-419
159. Gibril F., Venzon D.J., Ojeaburu J.V., et al. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86 (2001) 5282-5293
160. Norton J.A., Alexander H.R., Fraker D.L., et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 234 (2001) 495-505
161. MacFarlane M.P., Fraker D.L., Alexander H.R., et al. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 118 6 (1995) 973-979 discussion 979-80.
162. Hausman Jr. M.S., Thompson N.W., Gauger P.G., et al. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136 (2004) 1205-1211
163. Thompson N.W. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 243 (1998) 495-500
164. Tonelli F., Fratini G., Nesi G., et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 244 (2006) 61-70
165. Bartsch D.K., Fendrich V., Langer P., et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242 (2005) 757-764
166. Roche A., Girish B.V., de Baere T., et al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology 51 (2004) 1751-1756
167. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (2005) 1590-1602
168. Miller C.A., and Ellison E.C. Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin N Am 7 (1998) 863-879
169. McEntee G.P., Nagourney D.M., Kvols L.K., et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 (1990) 1091-1096
170. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169 (1995) 36-42 discussion 42-43.
171. Norton J.A., Sugarbaker P.H., Doppman J.L., et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 203 (1986) 352-359
172. Yao K.A., Talamonti M.S., Nemcek A., et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130 (2001) 677-682
173. Norton J.A., Warren R.S., Kelly M.G., Zuraek M.B., and Jensen R.T. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134 (2003) 1057-1063
174. Touzious J.G., Kiely J.M., Pitt S.C., et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg 241 (2005) 776-783
175. Munsunuru S., Chen H., Rajpal S., et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 141 (2006) 1000-1004
176. Landry C.S., Scoggins C.R., McMasters K.M., et al. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol 97 (2008) 253-258
177. Berber E., Flesher N., and Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26 (2002) 985-990
178. Mazzaglia P.J., Berber E., Milas M., et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142 (2007) 10-19
179. Gillams A., Cassoni A., Conway G., et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 30 (2005) 435-441
180. Lang H., Oldhafer K.J., Weimann A., et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 225 (1997) 347-354
181. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 66 (1998) 1307-1312
182. Rosenau J., Bahr M.J., von Wasielewski R., et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 73 (2002) 386-394
183. Olausson M., Friman S., Herlenius G., et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 13 (2007) 327-333
184. Pascher A., Klupp J., and Neuhaus P. Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 19 (2005) 637-648
185. Perry L.J., Stuart K., Stokes K.R., et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116 (1994) 1111-1116 discussion 1116-7.
186. Falconi M., Bassi C., Bonora A., et al. Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumours. Dig Surg 16 (1999) 32-38
187. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-435
188. Osborne D.A., Zervos E.E., Strosberg J., et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13 (2006) 572-581
189. Ho A.S., Picus J., Darcy M.D., et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 188 (2007) 1201-1207
190. Ducreux M., Ruszniewski P., Chayvialle J.A., et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95 (2000) 3276-3281
191. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (2008) 2124-2130
192. Bilimoria K.Y., Bentrem D.J., Merkow R.P., et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 205 (2007) 558-563
193. Bilimoria K.Y., Talamonti M.S., Tomlinson J.S., et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 247 (2008) 490-500
194. Pape U.F., Jann H., Müller-Nordhorn J., et al. Progostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113 (2008) 256-265
195. Ellison E.C. Zollinger-Ellison syndrome: a personal perspective. Am Surg 74 (2008) 563-571
196. Rawson A.B., England M.T., Gilliam G.G., et al. Zollinger-Ellison syndrome with diarrhoea and malabsorption. Observations on a patient before and after pancreatic islet-cell tumour removal without resort to gastric surgery. Lancet 2 (1960) 131-134
197. Parrish J.A., and Rawline D.C. Intestinal mucosa in the Zollinger-Ellison syndrome. Gut 6 (1965) 286-289
198. Waddell W.R., Coppinger W.R., and Loughry R.W. Pancreaticoduodenectomy for Zollinger-Ellison syndrome. Ann Surg 168 (1968) 641-654
199. Oberhelman Jr. H.A. Excisional therapy for ulcerogenic tumors of the duodenum: long-term results. Arch Surg 104 (1972) 447-453
200. Zollinger R.M., Ellison E.C., Fabri P.J., et al. Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty-five-year appraisal. Ann Surg 192 (1980) 422-430
201. Bonfils S., Landor J.H., Mignon M., et al. Results of surgical management in 92 consecutive cases with Zollinger-Ellison syndrome. Ann Surg 194 (1981) 692-697
202. Wilson S.D. The role of surgery in children with the Zollinger-Ellison syndrome. Surgery 92 (1982) 682-692
203. Friesen S.R. Treatment of the Zollinger-Ellison syndrome. A 25 year assessment. Am J Surg 143 (1982) 331-338
204. Wolfe M.M., Alexander R.W., and McGuigan J.E. Extrapancreatic extraintestinal gastrinoma: effective treatment by surgery. N Engl J Med 306 (1982) 1533-1536
205. Barreras R.F., Mack E., Goodfriend T., and Damm M. Resection of gastrinoma in the Zollinger-Ellison syndrome. Gastroenterology 82 (1982) 953-956
206. Malagaleda J.R., Edis A.J., Adson M.A., et al. Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 84 (1983) 1524-1532
207. Deveney C.W., Deveney K.S., and Way L.W. The Zollinger-Ellison syndrome-23 years later. Ann Surg 188 (1978) 384-393
208. Landor J.H. Control of the Zollinger-Ellison syndrome by excision of primary and metastatic tumor. Am J Surg 147 (1984) 406-409
209. Stabile B.E., and Passaro Jr. E. Benign and malignant gastrinoma. Am J Surg 149 (1985) 144-150
210. Miyata M., Nakao K., Sakamoto T., et al. Removal of mesenteric gastrinoma: a case report. Surgery 99 (1986) 245-248
211. Vogel S.B., Wolfe M.M., McGuigan J.E., et al. Localization and resection of gastrinomas in Zollinger-Ellison syndrome. Ann Surg 205 (1987) 550-556
212. Howard T.J., Zinner M.J., Stabile B.E., and Passaro Jr. E. Gastrinoma excision for cure. A prospective analysis. Ann Surg 211 (1990) 9-14
213. Kaplan E.L., Horvath K., Udekwu A., et al. Gastrinomas: a 42-year experience. World J Surg 14 (1990) 365-375 discussion 375-6
214. Declore R., and Friesen S.R. Rule of pancreatoduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome. Surgery 112 (1992) 1016-1022 discussion 1022-3
215. Farley D.R., vanHeerden J.A., Grant C.S., et al. The Zollinger-Ellison syndrome. A collective experience. Ann Surg 215 (1992) 561-569 discussion 569-70
216. Norton J.A., Doppman J.L., and Jensen R.T. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg 215 (1992) 8-18